NUZ
Healthcare & BiotechPULLBACK$0.060
as of 2026-07-27
5d return
-7.7%
20d return
+1.7%
60d return
-27.7%
RSI 14
24.0
vs 52w high
-64.7%
vs 52w low
+3.5%
SMA 20
Below
SMA 50
Below
Price · Volume · Broker flow
Markers = announcements (red triangle = price-sensitive). Volume amber = ≥2× ADV spike. Flow bars stacked per broker group. Flow lags T+3.
Loading chart…
Announcements — last 30 days
NUZ has completed enrolment of 250 ALS patients in Regimen I of the HEALEY platform trial ahead of schedule, enabling acceleration of topline efficacy/safety readout to late Q2 2027—a material de-risking milestone that removes execution risk from the lead program. The rapid recruitment (fastest in the platform trial history) and earlier data readout represent a significant value inflection point for this $51m market-cap clinical-stage company.
- 2026-07-01Change of Director's Interest Notice
- 2026-06-30Proposed issue of securities - NUZ